key: cord-0936364-ppnasxso
authors: Shaw, Rebecca J.; Abrams, Simon T.; Austin, James; Taylor, Joseph M.; Lane, Steven; Dutt, Tina; Downey, Colin; Du, Min; Turtle, Lance; Baillie, J. Kenneth; Openshaw, Peter J.M.; Wang, Guozheng; Semple, Malcolm G.; Toh, Cheng-Hock
title: Circulating histones play a central role in COVID-19-associated coagulopathy and mortality
date: 2021-04-08
journal: Haematologica
DOI: 10.3324/haematol.2021.278492
sha: b63e635901f0b3b99557de83c689a9d84b09e74a
doc_id: 936364
cord_uid: ppnasxso

nan

COVID-19 has highlighted the lethal consequences of immunothrombosis; i.e., the cross-talk between coagulation, inflammation and the innate immune system. Patients with immunothrombosis have significant immune cell death, 1 which can release pro-coagulant 2 and cytotoxic 3 histones. Histones are small, positivelycharged proteins that are typically found within the cell nucleus and which bind to negatively-charged DNA. We hypothesize that circulating histones play a central role in critically-ill COVID-19 patients. This translational study demonstrates that admission histone levels are significantly elevated with increasing severity of COVID-19 infection (Mild, median=2.6 μg/mL [IQR=0.7-7.6], Moderate, 10.5 μg/mL [3.5-27.2] , Critical, 20.0 μg/mL [6.2-33 .0], Non-survivors, 29.6 μg/mL [11.2-60 .0]; P<0.001). Circulating histones associated with severe coagulopathy, inflammation and organ injury markers, including cardiac troponin. Extracellular histone levels on admission are associated with poor outcomes and independently predict 28-day mortality of hospitalized COVID-19 patients. This is the first report to indicate that circulating histones, released following immune cell death, may play a central pathological role in severe SARS-CoV-2 infection.

COVID-19 was the cause of more than two million deaths worldwide by February 2021, 4 resulting from respiratory and multi-organ failure, 5 with evidence of pulmonary thrombosis at post-mortem. 6 These patients have extensive immune cell death, 1 a strong acute-phase inflammatory response and coagulopathy, as well as cardiac injury. 1, 5 Cell death can release histones, and extracellular histones are cytotoxic, pro-inflammatory 7 and pro-coagulant, 2 leading to pulmonary thrombosis. 8 Extracellular histones also trigger interleukin-6 (IL-6) release to induce an acute phase response, including elevation of C-reactive protein (CRP), which, in turn, reduces histone toxicity. 9 High levels of circulating histones initiate an alternative coagulation pathway during sepsis, 2 mediate multiple organ injury 3 and correlate with adverse clinical outcomes, including death. 10 We therefore hypothesized that high levels of histones are present in severe SARS-CoV-2 infection, and act as major mediators of coagulopathy and mortality in COVID-19 disease.

In this study, adult COVID-19 patients (n=113) were recruited at the Royal Liverpool University Hospital from 30 th March 2020 to 16 th May 2020. Patients were selected using the ISARIC WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK. Inclusion criteria were: (1) swab positive or high likelihood of infection or (2) ≥1 of the following symptoms: fever ≥38°C, new cough, dyspnea or tachypnea and admitted to a healthcare facility. 11 Patients were categorized into four groups: 1) Mild (minor respiratory symptoms to exclude shortness of breath OR incidental finding, where the patient required admission to hospital for reasons other than COVID-19 (such as for frailty) and was otherwise asymptomatic of COVID-19); 2) Moderate (dyspnea, i.e., patient symptomatic with shortness of breath OR hypoxia, defined by oxygen saturations on pulse oximeter of ≤93% or requiring supplementary oxygen to maintain oxygen saturations ≥96%); 3) Critical disease (respiratory failure requiring the administration of continuous positive airway pressure (CPAP) to maintain oxygen saturations ≥96% OR invasive ventilation in a critical care setting); 4) Non-survivors (patients who died within 28 days of hospital admission).

Circulating histones were quantified in patient plasma on admission (as described previously) 8, 12 and associations with severity of infection, coagulation, inflammatory and organ injury markers were analyzed. Severity of infection was determined by the patient's most severe clinical state throughout hospital admission, according to the previously described definitions. Cytokines were measured using a Luminex-based bead array, as per manufacturer's instructions (Thermo-Fisher Scientific). Outcome measures included ventilator-support days, length of hospital stay, and 28-day mortality. The Kruskall-Wallis test was used to compare continuous variables, presented as median (interquartile range; IQR); the Fisher Exact/χ 2 test for comparison of categorical variables, presented as counts (percentage). Circulating histone levels were measured by Western Blot, using purified histone as the standard, and analyzed either as continuous variables or categorized based on a previously-determined threshold for cytotoxicity (30 μg/mL). 3, 7 The Mann-Whitney U test was used to compare categorical histone levels to continuous clinical variables. Correlation analysis was performed using Spearman's rank. A Receiver Operating Characteristic (ROC) curve analysis and multivariate regression (adjusted for age, gender, ethnicity and co-morbidities) assessed admission histone levels in predicting 28-day mortality. Kaplan-Meier survival curve analysis was performed to analyze the probability of mortality over time. Statistical tests were performed on SPSS (IBM, version 25). A 2-tailed P value of <0.05 was considered significant.

The study involved 113 COVID-19 patients (Table 1) : median age 65.0 years (IQR=51.0-78.0 years), 65 patients were male (57.5%), 96 of white ethnicity (85.0%). Disease severity was associated with coagulation activation (Table 1) , characterized by elevated D-dimer (P=0.017) and prolonged prothrombin time (P=0.005), and a pro-inflammatory phenotype characterized by elevated CRP (P<0.001) and IL-6 (P=0.002) on hospital admission, as well as with hypoxia and cardiac injury ( Table 1 ). The median hospital stay was 10 days (IQR, 3-20 days) and 25 patients (22.1%) died within 28 days.

Circulating histone levels on admission were significantly elevated in COVID-19 patients compared to normal controls and were associated with increasing severity of infection ( Figure 1A Circulating histone levels strongly correlated with D-dimer levels (R=0.606), indicating the potential involvement of extracellular histones in COVID-19 coagulopathy. Positive association with organ injury markers, including bilirubin (R=0.531), creatinine (R=0.501) and cardiac troponin (R=0.486), indicates the possible role of histone-induced cytotoxicity in multiple organ injury. Strong associations with fibrinogen (R=0.632), CRP (R=0.735) and IL-6 (R=0.677) confirmed histone-initiated acute phase response. 9 Negative correlation with lymphocyte count (R=-0.446) suggests that lymphocyte and other immune cell death might be a major source of circulating histones in COVID-19 infection.

Adopting a 30 μg/mL cytotoxic histone threshold, 3 Circulating histone levels were significantly higher in non-survivors than those who survived (29.6 μg/mL Typical Western Blots (A) and quantification (B) of histone levels in healthy controls (n=12), mild (n=30), moderate (n=38), critical disease (n=20) and non-survivors (n=25) with COVID-19 infection. Circulating histone levels were higher with increasing disease severity (P<0.001). Histone levels were higher in non-survivors compared to the moderate (P=0.023), mild groups (P<0.001) and to normal healthy controls (P<0.001). Histone levels were higher in the critical group compared to mild groups (P<0.001) and normal healthy controls (P<0.001). Histone levels were higher in the moderate group compared to the mild group (P=0.007) and normal healthy controls (P=0.002). (C) Multivariate analysis of crude and adjusted odds ratios (with patients adjusted for age, gender, Black and Ethnic Minorities (BAME) and comorbidities including smoking, hypertension, asthma/COPD, diabetes, ischemic heart disease and chronic kidney disease). Circulating histone levels ≥30 μg/mL were independently associated with 28-day mortality. (D) Kaplan-Meier survival curve for the probability of mortality during the 28-day period. Patients were stratified based on circulating histones levels on admission (<30 μg/mL vs. ≥ 30 μg/mL). (E) Diagram to propose that circulating histones play a central pathological role in the development of severe COVID-19. Figure 1D, P<0.001 ).

Coagulopathy has emerged as a key feature of severe COVID-19 and has been linked to increased mortality. 13 It has been documented that extracellular histones, released following cell death, are drivers of coagulation by activating platelets, 7 generating thrombin 2 and damaging endothelial cells 8 to induce coagulopathy in critical illness. 3 This is the first report to demonstrate high levels of circulating histones in SARS-CoV-2 infection, with levels strongly associated with coagulopathy. This suggests their involvement in thrombosis in severe cases. 14 High levels of circulating histones reflect the extent of cellular death, such as lymphopenia or NETosis, 15 which may be a major source of circulating histones in COVID-19. Histone release following cell death triggers IL-6 release to induce an acute-phase response. 8 We found that circulating histone levels significantly correlated with IL-6 and acute-phase protein levels, including fibrinogen and CRP, indicating histone-induced acute phase response in patients with COVID-19.

Extracellular histones disrupt cell membranes through phospholipid binding to induce cytotoxic effects on cells, including endothelial cells 8 and cardiomyocytes. 12 This study demonstrates circulating histones associated with cardiac injury, which is frequently observed in severe COVID-19 and associated with poor outcomes. 5 Therefore, the cytotoxic and pro-coagulant properties of circulating histones may be an underlying molecular mechanism contributing to disease severity and poor outcomes ( Figure 1E ).

In conclusion, this is the first report to quantify high levels of circulating histones in viral infection and demonstrate that extracellular histones play a central role in the development of immunothrombosis and critical illness in COVID-19.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Assembly of alternative prothrombinase by extracellular histones initiates and disseminates intravascular coagulation

Circulating histones are major mediators of multiple organ dysfunction syndrome in acute critical illnesses

COVID-19) Dashboard. 2020 [cited 18 th

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Autopsy findings and venous thromboembolism in patients with COVID-19

Histone-associated thrombocytopenia in patients who are critically ill

Circulating histones are mediators of trauma-associated lung injury

Human CRP Defends against the toxicity of circulating histones

Extracellular histones are major mediators of death in sepsis

Features of 20,133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Circulating histones are major mediators of cardiac injury in patients with sepsis

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Rebecca J. Shaw, 1,2* Simon T. Abrams, 1* James Austin, 1* Joseph M. Taylor, 3 Steven Lane, 4 Tina Dutt, 2 Colin Downey, 3 Min Du, 1 Lance Turtle, 1, 5 J. Kenneth Baillie, 6, 7 Peter J.M. Openshaw, 8 Guozheng Wang, 1